Certara, Inc. is engaged in model-informed drug development. The Company accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to efficiently carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services are underpinned by technologies such as regulatory submissions software, natural language processing and Bayesian analytics. It also develops scientific informatics software products used by the life sciences industry for in-silico research. It develops advanced modeling and biosimulation solutions used to predict the pharmacokinetic and pharmacodynamic properties. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 66 countries.
BörsenkürzelCERT
Name des UnternehmensCertara Inc
IPO-datumDec 11, 2020
CEODr. William F. (Bill) Feehery, Ph.D.
Anzahl der mitarbeiter1487
WertpapierartOrdinary Share
GeschäftsjahresendeDec 11
Addresse4 Radnor Corporate Center, Suite 350
StadtRADNOR
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl19087
Telefon14152378272
Websitehttps://www.certara.com/
BörsenkürzelCERT
IPO-datumDec 11, 2020
CEODr. William F. (Bill) Feehery, Ph.D.
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten